ChemoCentryx, Inc. (NASDAQ:CCXI) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, July 17th. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. Finally, BidaskClub cut shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $9.00.

ChemoCentryx (CCXI) traded down 1.95% during trading on Friday, hitting $7.03. 140,361 shares of the stock were exchanged. The stock’s 50 day moving average is $7.50 and its 200-day moving average is $7.83. ChemoCentryx has a one year low of $5.19 and a one year high of $10.80. The company’s market cap is $342.40 million.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The company had revenue of $8.94 million for the quarter. On average, equities research analysts expect that ChemoCentryx will post ($0.90) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/21/chemocentryx-inc-ccxi-lowered-to-sell-at-valuengine.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. American Century Companies Inc. grew its holdings in ChemoCentryx by 1.7% during the second quarter. American Century Companies Inc. now owns 41,442 shares of the biopharmaceutical company’s stock worth $388,000 after acquiring an additional 698 shares during the period. Wells Fargo & Company MN grew its holdings in ChemoCentryx by 3.2% during the second quarter. Wells Fargo & Company MN now owns 23,595 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 729 shares during the period. Teachers Advisors LLC grew its holdings in ChemoCentryx by 3.9% during the second quarter. Teachers Advisors LLC now owns 41,878 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 1,590 shares during the period. The Manufacturers Life Insurance Company grew its holdings in ChemoCentryx by 14.5% during the second quarter. The Manufacturers Life Insurance Company now owns 22,514 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 2,852 shares during the period. Finally, Voya Investment Management LLC grew its holdings in ChemoCentryx by 22.8% during the second quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 2,965 shares during the period. Institutional investors and hedge funds own 50.12% of the company’s stock.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.